Argenx Trading 8% Up In Morning Trade

Shares of argenx SE (ARGX) are up more than 8% Monday morning.

On Friday, the FDA had approved argenx's VYVGARTô for the treatment of adults patients with generalized myasthenia gravis.

Generalized myasthenia gravis is a rare and chronic neuromuscular disease characterized by debilitating and potentially life-threatening muscle weakness.

ARGX is at $337.02 currently. It has traded in the range of $248.21- $382.15 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT